GenVec reports net loss of $1.5 million for first quarter 2015

GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year. GenVec ended the first quarter of 2015 with $12.7 million in cash, cash equivalents, and investments.

First Quarter and Recent Corporate Highlights

  • In February, GenVec announced the initiation of the development of a vaccine against EV-D68, a strain of enterovirus responsible for causing potentially serious respiratory illness in people across 49 states and the District of Columbia in 2014. The company believes that its EV-D68 vaccine program will leverage the success it had with a similar type of virus, FMD, to develop a safe, effective molecular vaccine.
  • In March, GenVec announced a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and TheraBiologics' proprietary neural stem cell (NSC) technology.
  • In April, GenVec announced a new research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology (LMIV) under which GenVec will build new vaccine candidates based on its proprietary adenovectors isolated from gorillas and designed to deliver novel antigens discovered by the LMIV.
  • In April, GenVec announced that Michael Richman, president and chief executive officer at Amplimmune, a member of the AstraZeneca Group, joined our board of directors. Mr. Richman brings his extensive background in building biotechnology companies, strategic planning and deal structuring to GenVec.

"We remain excited with the prospects for our proprietary adenovector technology and its potential to deliver value to both patients and GenVec shareholders," said Douglas J. Swirsky, GenVec's president and CEO. "We intend to continue cost-effectively expanding the reach of our technology platform this year while supporting the efforts of our partner, Novartis, who continues to make progress on Phase 1/2 testing of CGF166 in patients with severe to profound hearing loss."

Financial Results for the Three Months Ended March 31, 2015

Revenues for the three-month period ended March 31, 2015 were $0.4 million, which represents a decrease of 81% as compared to revenues of $2.1 million in the comparable prior year period. The decrease in revenue for the three-month period ended March 31, 2015 is primarily a result of a decrease in revenue of $1.9 million associated with our hearing loss and balance disorders program with Novartis. This lower revenue resulted mainly from the achievement of a $2 million milestone in the collaboration during the first quarter of 2014, with no corresponding achievement in the first quarter of 2015. This decrease was partially offset by an increase in revenue of $0.2 million associated with our animal health program due to increased work scope. Our contract with the Department of Homeland Security (DHS) to perform work related to our animal health program ended in February 2015.

Operating expenses were $1.9 million for the three-month period ended March 31, 2015, which represents a decrease of 37% as compared to $3.1 million in the comparable prior year period.

General and administrative expenses for the three-month period ended March 31, 2015 decreased 46%, with an expense of approximately $1.3 million in 2015 as compared to $2.4 million in 2014. The decrease was primarily a result of lower facility costs related to the relocation of our corporate offices and professional costs. Partially offsetting these decreases were increased personnel costs.

Research and development expenses for the three-month period ended March 31, 2015 decreased 7%, from $0.7 million in 2014 to $0.6 million in 2015. The decrease in the three-month period ended March 31, 2015 was primarily a result of lower facility, professional and material costs, partially offset by higher personnel costs.

2015 Cash Guidance

For 2015, GenVec expects cash burn between $5 million and $7 million. The company believes that existing resources are sufficient to fund the company's operations into 2017.

Source:

GenVec, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
ESSA’s position statement on exercise guidelines for people with cancer